Regeneron Pharmaceuticals price to free cash flow REGN
Market value divided by free cash flow over the last twelve months, since 2013.
- Today, Nov 3, 2026
- 26.6×
- 10-year median
- 22.1×
- Against its 10-year history
- 70th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 7.9× to 52.8×
- Peer median
- 20.9×
Regeneron Pharmaceuticals' price to free cash flow is 26.6× as of Nov 3, 2026.
That is above its ten-year median of 22.1×, higher than on 70% of days in the last ten years.
Over that time it ranged from 7.9× in Jun 2022 to 52.8× in Nov 2016.
The median for 9 biotech stocks of a similar size is 20.9×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 26.3× | 15.5× | 26.3× |
| 2025 | 19.5× | 15.4× | 22.9× |
| 2024 | 22.8× | 21.6× | 39.7× |
| 2023 | 20.8× | 15.5× | 23.5× |
| 2022 | 15.5× | 7.9× | 16.4× |
| 2021 | 12.6× | 12.2× | 42.9× |
| 2020 | 32.6× | 18.6× | 42.5× |
| 2019 | 20.5× | 15.3× | 28.6× |
| 2018 | 24.1× | 22.2× | 35.9× |
| 2017 | 49.2× | 43.6× | 49.2× |
| 2016 | 46.2× | 35.6× | 81.3× |
| 2015 | 89.7× | 77.0× | 260× |
| 2014 | 78.2× | 66.5× | 100× |
| 2013 | 92.6× | 90.1× | 136× |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| REGNRegeneron Pharmaceuticals | 26.6× |
| VRTXVertex Pharmaceuticals | n/m |
| ONCBeOne Medicines | 30.2× |
| UTHRUnited Therapeutics | 23.7× |
| INCYIncyte | 12.7× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| EXELExelixis | 14.8× |
| NBIXNeurocrine Biosciences | 17.0× |
| HALOHalozyme Therapeutics | 18.2× |
| TECHBIO-TECHNE | 43.3× |
| Peer median | 20.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.